drugset / Trial / NCT00738985
Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors
Phase 4
Withdrawn
National Institute of Medical Sciences and Nutrition Salvador Zubiran
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To measure the percentage of patients who achieve all the treatment lipid goals being treated with ezetimibe/simvastatin 10/20 with or without MK0524A (1-2 g/day).
Timeline
- Start
- 2009-11
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ezetimibe | Unknown | 10 mg | — |
| Comparator | MK0524A | Unknown | 1 g | — |
| Comparator | MK0524A | Unknown | 2 g | — |
| Comparator | Simvastatin | Small molecule | 20 mg | — |